U.S. markets closed

Nanoform Finland Oyj (NANOFH.HE)

Helsinki - Helsinki Real Time Price. Currency in EUR
Add to watchlist
4.3480-0.0260 (-0.59%)
At close: 6:24PM EEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.3740
Bid4.3240 x N/A
Ask4.3480 x N/A
Day's Range4.3000 - 4.4000
52 Week Range3.9100 - 5.0990
Avg. Volume45,477
Market Cap289.579M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3480
Earnings DateAug 28, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      Nanoform Finland PLC, 2020 Half Year Financial Report, 28 August 2020 At 8:10 Am EEST

      Nanoform's half year financial report January-June 2020: Positive momentum continues to build after successful IPO, near-term business target: "to acquire more new customers in 2020 than in 2019" achieved in July.

    • PR Newswire

      Nanoform convenes EGM to elect Cynthia Schwalm as board member

      Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, will convene an extraordinary general meeting (EGM) on September 1, 2020 at 10 am Helsinki time to elect Cynthia Schwalm as a new board member. The notice to the EGM was published simultaneously with this release. Cynthia, a renowned Biotechnology CEO and pharmaceutical leader, began her career as an Oncology and Critical Care Nurse at the Albert Einstein Medical Center & Rutgers University Camden Medical Center, where she developed a patient-focused perspective. She then honed her leadership skills over 30+ years by orchestrating, in executive positions, the activities of top-tier global pharmaceutical organisations in the US, such as J&J; and Amgen. Further career highlights include her role as President and CEO of Ipsen and Eisai's North American Divisions.